Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712011 | 0.89 | LMNA (0.50) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL15956080 | 0.85 | NPC1 (0.57) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL12255202 | 0.83 | ALDH1A1 (0.50) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL13685349 | 0.81 | ALDH1A1 (0.51) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL670136 | 0.81 | LMNA (0.49) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL68851 | 0.81 | CYP4Z1 (0.62) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL1627244 | 0.80 | ALDH1A1 (0.68) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL16799957 | 0.79 | LMNA (0.50) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL11832497 | 0.79 | LMNA (0.47) | LMNAALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL18275144 | 0.79 | CYP4Z1 (0.48) | LMNAALDH1A1KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781451-B2 | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-20070265297-A1 | Thiazolopyridine Derivatives, Pharmaceut Ical Conditions Containing Them And Methods Of Treating Glucokinase Mediated Conditions | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| EP-1737870-A1 | THIAZOLOPYRIDINE DERIVATES, PHARMACEUTICAL CONDITIONS CONTAINING THEM AND METHODS OF TREATING GLUCOKINASE MEDIATED CONDITIONS | Novartis AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005095417-A1 | THIAZOLOPYRIDINE DERIVATES, PHARMACEUTICAL CONDITIONS CONTAINING THEM AND METHODS OF TREATING GLUCOKINASE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265297-A1 | Thiazolopyridine Derivatives, Pharmaceut Ical Conditions Containing Them And Methods Of Treating Glucokinase Mediated Conditions | GCK, GCKR, PCK1 | LMNA 3959/4885ALDH1A1 623/4885KDM4E 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.